274 related articles for article (PubMed ID: 21720102)
21. [Glucocorticoid and Bone. Efficacy and safety of bisphosphonate in treatment of glucocorticoid induced osteoporosis].
Tanaka I
Clin Calcium; 2014 Sep; 24(9):1371-8. PubMed ID: 25177010
[TBL] [Abstract][Full Text] [Related]
22. Denosumab in transfusion-dependent thalassemia osteoporosis: a randomized, placebo-controlled, double-blind phase 2b clinical trial.
Voskaridou E; Ntanasis-Stathopoulos I; Papaefstathiou A; Christoulas D; Dimopoulou M; Repa K; Papatheodorou A; Peppa M; Terpos E
Blood Adv; 2018 Nov; 2(21):2837-2847. PubMed ID: 30381400
[TBL] [Abstract][Full Text] [Related]
23. Combined effect of teriparatide and an anti-RANKL monoclonal antibody on bone defect regeneration in mice with glucocorticoid-induced osteoporosis.
Etani Y; Ebina K; Hirao M; Kitaguchi K; Kashii M; Ishimoto T; Nakano T; Okamura G; Miyama A; Takami K; Goshima A; Kanamoto T; Nakata K; Yoshikawa H
Bone; 2020 Oct; 139():115525. PubMed ID: 32645445
[TBL] [Abstract][Full Text] [Related]
24. Glucocorticoid induced osteoporosis.
Hu K; Adachi JD
Expert Rev Endocrinol Metab; 2019 Jul; 14(4):259-266. PubMed ID: 31094232
[TBL] [Abstract][Full Text] [Related]
25. Management of glucocorticoid-induced osteoporosis.
Rizzoli R; Adachi JD; Cooper C; Dere W; Devogelaer JP; Diez-Perez A; Kanis JA; Laslop A; Mitlak B; Papapoulos S; Ralston S; Reiter S; Werhya G; Reginster JY
Calcif Tissue Int; 2012 Oct; 91(4):225-43. PubMed ID: 22878667
[TBL] [Abstract][Full Text] [Related]
26. Prevention and Treatment of Glucocorticoid-Induced Osteoporosis in Adults: Consensus Recommendations From the Belgian Bone Club.
Laurent MR; Goemaere S; Verroken C; Bergmann P; Body JJ; Bruyère O; Cavalier E; Rozenberg S; Lapauw B; Gielen E
Front Endocrinol (Lausanne); 2022; 13():908727. PubMed ID: 35757436
[TBL] [Abstract][Full Text] [Related]
27. 2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis.
Buckley L; Guyatt G; Fink HA; Cannon M; Grossman J; Hansen KE; Humphrey MB; Lane NE; Magrey M; Miller M; Morrison L; Rao M; Robinson AB; Saha S; Wolver S; Bannuru RR; Vaysbrot E; Osani M; Turgunbaev M; Miller AS; McAlindon T
Arthritis Rheumatol; 2017 Aug; 69(8):1521-1537. PubMed ID: 28585373
[TBL] [Abstract][Full Text] [Related]
28. Glucocorticoid-induced osteoporosis: 2019 concise clinical review.
Adami G; Saag KG
Osteoporos Int; 2019 Jun; 30(6):1145-1156. PubMed ID: 30805679
[TBL] [Abstract][Full Text] [Related]
29. [Glucocorticoid-induced osteoporosis : treatment update].
Soen S
Clin Calcium; 2012 Feb; 22(2):229-35. PubMed ID: 22298077
[TBL] [Abstract][Full Text] [Related]
30. Cost-effectiveness of bisphosphonates for prevention of fracture related to glucocorticoid-induced osteoporosis in Malaysia.
Mohd-Tahir NA; Thomas P; Mohamed-Said MS; Makmor-Bakry M; Li SC
Int J Rheum Dis; 2018 Mar; 21(3):647-655. PubMed ID: 29105349
[TBL] [Abstract][Full Text] [Related]
31. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women.
Wensel TM; Iranikhah MM; Wilborn TW
Pharmacotherapy; 2011 May; 31(5):510-23. PubMed ID: 21923432
[TBL] [Abstract][Full Text] [Related]
32. The molecular etiology and treatment of glucocorticoid-induced osteoporosis.
Peng CH; Lin WY; Yeh KT; Chen IH; Wu WT; Lin MD
Tzu Chi Med J; 2021; 33(3):212-223. PubMed ID: 34386357
[TBL] [Abstract][Full Text] [Related]
33. Glucocorticoid-induced osteoporosis update.
Adami G; Saag KG
Curr Opin Rheumatol; 2019 Jul; 31(4):388-393. PubMed ID: 31045947
[TBL] [Abstract][Full Text] [Related]
34. Osteoporosis: now and the future.
Rachner TD; Khosla S; Hofbauer LC
Lancet; 2011 Apr; 377(9773):1276-87. PubMed ID: 21450337
[TBL] [Abstract][Full Text] [Related]
35. [Drug-induced osteoporosis].
Tanaka Y
Nihon Rinsho; 2007 Oct; 65 Suppl 8():394-8. PubMed ID: 18074570
[No Abstract] [Full Text] [Related]
36. Influence of glucocorticoids on the osteogenic differentiation of rat bone marrow-derived mesenchymal stem cells.
Zhou DA; Zheng HX; Wang CW; Shi D; Li JJ
BMC Musculoskelet Disord; 2014 Jul; 15():239. PubMed ID: 25027542
[TBL] [Abstract][Full Text] [Related]
37. Glucocorticoid-induced osteoporosis and osteonecrosis.
Weinstein RS
Endocrinol Metab Clin North Am; 2012 Sep; 41(3):595-611. PubMed ID: 22877431
[TBL] [Abstract][Full Text] [Related]
38. Prevention and treatment strategies for glucocorticoid-induced osteoporotic fractures.
Gourlay M; Franceschini N; Sheyn Y
Clin Rheumatol; 2007 Feb; 26(2):144-53. PubMed ID: 16670825
[TBL] [Abstract][Full Text] [Related]
39. Effects of quality indicator monitoring for glucocorticoid-induced osteoporosis and trends of drug treatment in a Japanese hospital.
Suda M; Suyama Y; Ohde S; Tsuda T; Sawada H; Kishimoto M; Okada M
Int J Rheum Dis; 2018 May; 21(5):975-981. PubMed ID: 29878618
[TBL] [Abstract][Full Text] [Related]
40. Ginsenosides Rg3 attenuates glucocorticoid-induced osteoporosis through regulating BMP-2/BMPR1A/Runx2 signaling pathway.
Zhang X; Chen K; Wei B; Liu X; Lei Z; Bai X
Chem Biol Interact; 2016 Aug; 256():188-97. PubMed ID: 27387537
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]